Amber Bucker1, Anna M Boers1, Joseph C J Bot1, Olvert A Berkhemer1, Hester F Lingsma1, Albert J Yoo1, Wim H van Zwam1, Robert J van Oostenbrugge1, Aad van der Lugt1, Diederik W J Dippel1, Yvo B W E M Roos1, Charles B L M Majoie1, Henk A Marquering2. 1. From the Department of Radiology (A.B., A.M.B., O.A.B., C.B.L.M.M., H.A.M.), Department of Biomedical Engineering & Physics (A.B., A.M.B., H.A.M.), and Department of Neurology (Y.B.W.E.M.R.), Academic Medical Center, the Netherlands; Department of Robotics and Mechatronics, University of Twente, the Netherlands (A.M.B.); Department of Radiology, VU Medical Center, the Netherlands (J.C.J.B.); Department of Public Health (H.F.L., D.W.J.D.), Department of Radiology (A.v.d.L.), and Department of Neurology (O.A.B., D.W.J.D.), Erasmus MC University Medical Center, the Netherlands; Department of Radiology, Texas Stroke Institute, Dallas (A.J.Y.); and Department of Radiology (O.A.B., W.H.v.Z.) and Department of Neurology (R.J.v.O.), Maastricht University Medical Center, the Netherlands. 2. From the Department of Radiology (A.B., A.M.B., O.A.B., C.B.L.M.M., H.A.M.), Department of Biomedical Engineering & Physics (A.B., A.M.B., H.A.M.), and Department of Neurology (Y.B.W.E.M.R.), Academic Medical Center, the Netherlands; Department of Robotics and Mechatronics, University of Twente, the Netherlands (A.M.B.); Department of Radiology, VU Medical Center, the Netherlands (J.C.J.B.); Department of Public Health (H.F.L., D.W.J.D.), Department of Radiology (A.v.d.L.), and Department of Neurology (O.A.B., D.W.J.D.), Erasmus MC University Medical Center, the Netherlands; Department of Radiology, Texas Stroke Institute, Dallas (A.J.Y.); and Department of Radiology (O.A.B., W.H.v.Z.) and Department of Neurology (R.J.v.O.), Maastricht University Medical Center, the Netherlands. h.a.marquering@amc.uva.nl.
Abstract
BACKGROUND AND PURPOSE:Ischemic lesion volume (ILV) on noncontrast computed tomography at 1 week can be used as a secondary outcome measure in patients with acute ischemic stroke. Twenty-four-hour ILV on noncontrast computed tomography has greater availability and potentially allows earlier estimation of functional outcome. We aimed to assess lesion growth 24 hours after stroke onset and compare the associations of 24-hour and 1-week ILV with functional outcome. METHODS: We included 228 patients from MR CLEAN trial (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands), who received noncontrast computed tomography at 24-hour and 1-week follow-up on which ILV was measured. Relative and absolute lesion growth was determined. Logistic regression models were constructed either including the 24-hour or including the 1-week ILV. Ordinal and dichotomous (0-2 and 3-6) modified Rankin scale scores were, respectively, used as primary and secondary outcome measures. RESULTS:Median ILV was 42 mL (interquartile range, 21-95 mL) and 64 mL (interquartile range: 30-120 mL) at 24 hours and 1 week, respectively. Relative lesion growth exceeding 30% occurred in 121 patients (53%) and absolute lesion growth exceeding 20 mL occurred in 83 patients (36%). Both the 24-hour and 1-week ILVs were similarly significantly associated with functional outcome (both P<0.001). In the logistic analyses, the areas under the curve of the receiver-operator characteristic curves were similar: 0.85 (95% confidence interval, 0.80-0.90) and 0.87 (95% confidence interval, 0.82-0.91) for including the 24-hour and 1-week ILV, respectively. CONCLUSIONS: Growth of ILV is common 24-hour poststroke onset. Nevertheless, the 24-hour ILV proved to be a valuable secondary outcome measure as it is equally strongly associated with functional outcome as the 1-week ILV. CLINICAL TRIAL REGISTRATION: URL: http://www.isrctn.com. Unique identifier: ISRCTN10888758.
RCT Entities:
BACKGROUND AND PURPOSE:Ischemic lesion volume (ILV) on noncontrast computed tomography at 1 week can be used as a secondary outcome measure in patients with acute ischemic stroke. Twenty-four-hour ILV on noncontrast computed tomography has greater availability and potentially allows earlier estimation of functional outcome. We aimed to assess lesion growth 24 hours after stroke onset and compare the associations of 24-hour and 1-week ILV with functional outcome. METHODS: We included 228 patients from MR CLEAN trial (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands), who received noncontrast computed tomography at 24-hour and 1-week follow-up on which ILV was measured. Relative and absolute lesion growth was determined. Logistic regression models were constructed either including the 24-hour or including the 1-week ILV. Ordinal and dichotomous (0-2 and 3-6) modified Rankin scale scores were, respectively, used as primary and secondary outcome measures. RESULTS: Median ILV was 42 mL (interquartile range, 21-95 mL) and 64 mL (interquartile range: 30-120 mL) at 24 hours and 1 week, respectively. Relative lesion growth exceeding 30% occurred in 121 patients (53%) and absolute lesion growth exceeding 20 mL occurred in 83 patients (36%). Both the 24-hour and 1-week ILVs were similarly significantly associated with functional outcome (both P<0.001). In the logistic analyses, the areas under the curve of the receiver-operator characteristic curves were similar: 0.85 (95% confidence interval, 0.80-0.90) and 0.87 (95% confidence interval, 0.82-0.91) for including the 24-hour and 1-week ILV, respectively. CONCLUSIONS: Growth of ILV is common 24-hour poststroke onset. Nevertheless, the 24-hour ILV proved to be a valuable secondary outcome measure as it is equally strongly associated with functional outcome as the 1-week ILV. CLINICAL TRIAL REGISTRATION: URL: http://www.isrctn.com. Unique identifier: ISRCTN10888758.
Authors: W Taylor Kimberly; Bruna Garbugio Dutra; Anna M M Boers; Heitor C B R Alves; Olvert A Berkhemer; Lucie van den Berg; Kevin N Sheth; Yvo B W E M Roos; Aad van der Lugt; Ludo F M Beenen; Diederik W J Dippel; Wim H van Zwam; Robert J van Oostenbrugge; Hester F Lingsma; Henk Marquering; Charles B L M Majoie Journal: JAMA Neurol Date: 2018-04-01 Impact factor: 18.302
Authors: Anna M M Boers; Ivo G H Jansen; Scott Brown; Hester F Lingsma; Ludo F M Beenen; Thomas G Devlin; Luis San Román; Ji-Hoe Heo; Marc Ribó; Mohammed A Almekhlafi; David S Liebeskind; Jeanne Teitelbaum; Patricia Cuadras; Richard du Mesnil de Rochemont; Marine Beaumont; Martin M Brown; Albert J Yoo; Geoffrey A Donnan; Jean Louis Mas; Catherine Oppenheim; Richard J Dowling; Thierry Moulin; Nelly Agrinier; Demetrius K Lopes; Lucía Aja Rodríguez; Kars C J Compagne; Fahad S Al-Ajlan; Jeremy Madigan; Gregory W Albers; Sebastien Soize; Jordi Blasco; Stephen M Davis; Raul G Nogueira; Antoni Dávalos; Bijoy K Menon; Aad van der Lugt; Keith W Muir; Yvo B W E M Roos; Phil White; Peter J Mitchell; Andrew M Demchuk; Wim H van Zwam; Tudor G Jovin; Robert J van Oostenbrugge; Diederik W J Dippel; Bruce C V Campbell; Francis Guillemin; Serge Bracard; Michael D Hill; Mayank Goyal; Henk A Marquering; Charles B L M Majoie Journal: JAMA Neurol Date: 2019-02-01 Impact factor: 18.302
Authors: Eckhard Schlemm; Thies Ingwersen; Alina Königsberg; Florent Boutitie; Martin Ebinger; Matthias Endres; Jochen B Fiebach; Jens Fiehler; Ivana Galinovic; Robin Lemmens; Keith W Muir; Norbert Nighoghossian; Salvador Pedraza; Josep Puig; Claus Z Simonsen; Vincent Thijs; Anke Wouters; Christian Gerloff; Götz Thomalla; Bastian Cheng Journal: Nat Commun Date: 2021-05-10 Impact factor: 14.919
Authors: Anke Wouters; David Robben; Soren Christensen; Henk A Marquering; Yvo B W E M Roos; Robert J van Oostenbrugge; Wim H van Zwam; Diederik W J Dippel; Charles B L M Majoie; Wouter J Schonewille; Aad van der Lugt; Maarten Lansberg; Gregory W Albers; Paul Suetens; Robin Lemmens Journal: Stroke Date: 2021-09-30 Impact factor: 7.914
Authors: Samantha E Spellicy; Erin E Kaiser; Michael M Bowler; Brian J Jurgielewicz; Robin L Webb; Franklin D West; Steven L Stice Journal: Transl Stroke Res Date: 2019-12-06 Impact factor: 6.829
Authors: K C J Compagne; A M M Boers; H A Marquering; O A Berkhemer; A J Yoo; L F M Beenen; R J van Oostenbrugge; W H van Zwam; Y B W E M Roos; C B Majoie; A C G M van Es; A van der Lugt; D W J Dippel; H Lingsma Journal: Eur Radiol Date: 2018-07-09 Impact factor: 5.315
Authors: Luuk Dekker; Victor J Geraedts; Hajo Hund; Suzanne C Cannegieter; Raul G Nogueira; Mayank Goyal; Ido R van den Wijngaard Journal: Interv Neurol Date: 2018-01-25